Vioxx Withdrawal Has Not Affected Merck's Belief In DTC Advertising
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck will continue to support its products with direct-to-consumer advertising campaigns despite the withdrawal of Vioxx, CEO Ray Gilmartin said Jan. 11 at the J.P. Morgan health care conference in San Francisco
You may also be interested in...
Vioxx DTC Ads Do Not Undercut “Learned Intermediary” Defense, Merck Says
“We think our DTC ads are wholly consistent with the philosophy underlying the learned intermediary rule,” General Counsel Frazier says. Merck expects the first Vioxx personal injury trial will commence in the first half of 2005 in either Texas or Alabama.
Merck/Schering Unbranded Ad Spotlights “Two Sources” Of High Cholesterol
The TV commercial launched three days after FDA approved the joint venture’s Zocor/Zetia combination Vytorin. The ad contains no suggestion of a branded product but highlights the hereditary and dietary causes of high cholesterol.
Natrecor Use Should Be Limited, Independent Panel Convened By J&J Says
The cardiologist panel calls for use of the congestive heart failure therapy to be "strictly limited" to patients that present with symptoms in the hospital setting. The expert panel also recommends that Scios "immediately undertake" a professional educational campaign about Natrecor's appropriate uses.